Tag / Shkreli

In August 2015, Turing Pharmaceuticals acquired the rights to Daraprim, a decades-old, lifesaving drug used to cure a rare parasitic infection. Shortly after this acquisition, CEO Martin Shkreli announced that the drug would retail for $750 per tablet, a 5555 percent increase over the previous price of $13.50. For weeks, this story dominated the headlines…